Improvement of HbA1c in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis Treated with bDMARDs.

Open Access Rheumatol · 2021 · PMC8092350 · PMID 33953620

Europe PMC DOI

hedged sentence

0.0470

closest p · 0.9× alpha

0.0470

boldest claim

The sentences

a statistical trendp=0.047actually significant

The ANOVA test did not showe a significant difference between the bDMARD treatments; rather, it showed only a statistical trend towards treatment with tocilizumab and sarilumab vs anti TNF (p=0.047).

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.